Love Your Lungs Week is a reminder that lung health depends on more than prevention. It also depends on better testing, clear medical conversations and earlier answers for people at higher risk.
Early detection is central to lung cancer outcomes. When cancer is found sooner, treatment can begin at a stage when it is more likely to be effective. That makes practical diagnostic tools an important part of improving the lung cancer pathway.
Cizzle Bio is advancing CIZ1B, a minimally invasive biomarker blood test for lung cancer. The test is being developed to support clinical decision-making alongside LDCT and other standard diagnostic approaches.
CIZ1B is being developed as a complementary tool that may help clinicians assess risk, guide next steps and support earlier investigation.
Love your lungs. Know your risk. Speak to your healthcare provider.
Cizzle Biotechnology Holdings plc (LON:CIZ) is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.
